Adjuvant therapy of hormone-positive and invasive breast cancer in the early stages of women with postmenopausal women.
Advocate therapy for invasive breast cancer at an early stage in women at postmenopausal period has been expanded; standard therapy was carried out on tamoxifen with a length of 5 rooks.
Therapy of first-line hormone-dependent breast cancer with extended breast cancer in postmenopausal women.
Likuvannya widespread forms of breast cancer in women with postmenopausal women (naturally abnormally caused by the piece), after relapse, but the progression of increased severity, yakimyu antagonized therapy with antiestrogens.
Neoadjuvant therapy in postmenopausal women with hormone-positive, HER-2-negative breast cancer, cannot be treated chemically and is not shown in a non-invasive way.
The effectiveness of the drug for patients with hormone-negative breast cancer has not been reported.